FDA Approves First Medication for Chronic Lung Disease Bronchiectasis
The FDA has approved Brinsupri, the first medication specifically targeting non-cystic fibrosis bronchiectasis, offering new hope for patients with this chronic lung condition.
In a landmark development for respiratory health, the U.S. Food and Drug Administration (FDA) has approved the first-ever drug targeting non-cystic fibrosis bronchiectasis (NCFB), a persistent lung condition that impairs the airways and promotes mucus buildup. The newly approved medication, insmed's daily oral pill branded as Brinsupri, offers a new treatment option for patients suffering from this chronic disease.
Brinsupri was approved following successful results in a Phase 3 clinical trial conducted last year, demonstrating its efficacy in reducing lung exacerbations associated with bronchiectasis. The drug works by inhibiting the enzyme DPP1, which is involved in neutrophilic inflammation—a core component of the disease’s pathology. By targeting this enzyme, Brinsupri addresses a fundamental cause of lung damage and recurrent infections in affected individuals.
According to the American Lung Association, bronchiectasis affects approximately 350,000 to 500,000 adults in the United States. The condition results from damaged or scarred airways, commonly after infections or other lung injuries, leading to impaired mucus clearance. This creates a conducive environment for persistent bacterial infections, further damaging lung tissue.
Insmed acquired Brinsupri from AstraZeneca for $30 million and is actively exploring its application for other conditions like chronic rhinosinusitis. The company plans to price the drug at an annual list cost of $88,000 in the U.S. and has already sought approval for markets in Europe, the UK, and Japan.
Experts are optimistic about Brinsupri’s potential to transform bronchiectasis treatment. Dr. Doreen Addrizzo-Harris from NYU Langone Health highlighted that this medication might establish a new standard of care by directly targeting inflammation and addressing a root cause of disease exacerbations.
This approval marks a significant advance in respiratory medicine, providing hope for improved management and quality of life for individuals living with bronchiectasis.
Source: https://medicalxpress.com/news/2025-08-fda-drug-chronic-lung-condition.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Neural Navigation: Advanced Computer Models Map Brain's Tiny Blood Vessels
Researchers have developed advanced computer models to map and understand the highly complex blood flow regulation in the brain's smallest vessels, offering new insights into neurological health and disease.
Understanding Semen Allergies: A Hidden but Common Condition
Semen allergies, known as seminal plasma hypersensitivity, affect many women and can cause symptoms from mild irritation to severe reactions. Learn about symptoms, diagnosis, and treatment options for this hidden condition.
Breakthrough in Leukemia Treatment: Immune Cell Discovery Offers New Hope
Scientists have identified a unique immune cell linked to aggressive leukemia, paving the way for innovative therapies that could improve long-term survival and reduce relapse in blood cancer patients.
Men's Awareness of Testicular Cancer: A Critical Public Health Gap
A new survey highlights the critical gap in men's awareness of testicular cancer, emphasizing the importance of early self-exams and education for young men at risk.